NHS Expands Access to Weight-Loss Injections for Heart Disease Patients
In a significant shift in cardiovascular care, more than a million individuals with heart disease are poised to receive weight-loss injections through the NHS. This move aims to reduce the risk of life-threatening events such as heart attacks and strokes.
New Eligibility Criteria and Clinical Evidence
Under updated guidance from the National Institute for Health and Care Excellence (NICE), patients who have experienced a heart attack or stroke will now qualify for weekly Wegovy injections. This treatment will complement existing therapies, including cholesterol-lowering statins, blood pressure medications, and lifestyle advice.
This marks the first time NICE has approved such a drug in the UK specifically for preventing further heart problems, rather than solely for weight management. Previously, medications like Wegovy and Ozempic were primarily used for obesity and diabetes.
Growing research indicates these drugs may directly benefit the heart and blood vessels, lowering the likelihood of future cardiovascular events. The decision follows the landmark SELECT trial, which involved over 17,000 patients with cardiovascular disease.
Trial Results and Broader Implications
Participants in the trial received weekly semaglutide injections—the active component in Wegovy—alongside standard care. Results showed a 20% reduction in major heart events compared to those given a placebo. Notably, benefits emerged early in the study, even before significant weight loss occurred, suggesting direct cardiovascular effects.
Heart disease remains a leading cause of death in the UK, accounting for more than 460 daily fatalities. Annually, over 200,000 people suffer heart attacks or strokes, with around eight million living with cardiovascular conditions.
An estimated 1.2 million individuals with a body mass index (BMI) above 27 meet the new eligibility criteria, broadening access beyond previous restrictions. Wegovy was previously available on the NHS only through specialist services for severe obesity, typically for those with a BMI of 35 or higher.
Expert Opinions and Practical Considerations
Helen Knight, NICE's director of medicines evaluation, emphasized the importance of this decision for patients living in fear of recurrent events. She stated it provides an additional layer of protection alongside existing treatments.
Dr. Sunil Gupta, a GP and clinical adviser to NICE, highlighted that this offers a crucial new option for high-risk patients. He encouraged eligible individuals to consult their GPs.
However, specialists like Dr. Oliver Guttmann, a consultant cardiologist at St Bartholomew's Hospital, urged caution. He noted practical challenges, including costs, supply issues, and the need to target the right patients. Dr. Guttmann described the shift from viewing these as 'obesity drugs' to 'cardiovascular therapies that also aid weight loss.'
Concerns Over Implementation and Equity
Professor Riyaz Patel, a cardiologist at University College London, warned of potential 'postcode lotteries' if access is not managed uniformly across the NHS. He stressed the importance of equitable distribution to avoid disparities based on location.
Juliet Bouverie, chief executive of the Stroke Association, welcomed the new option but emphasized the need for personalized care, as stroke survivors have varying needs.
Sebnem Avsar Tuna, general manager of Novo Nordisk UK, noted that this approval provides clinicians with the first GLP-1 receptor agonist proven to reduce cardiovascular risks in high-risk groups.
NICE expressed confidence that the recommendation balances clinical benefits with cost-effectiveness, paving the way for broader integration into routine cardiovascular care over the coming years.
